TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1095514

Group type: EXPERIMENTAL
Intervention: Lofepramine (210 mg daily for 20 days)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Imipramine (150 mg daily for 20 days)
Number of subjects: 49
Study: 30744268

Group type: EXPERIMENTAL
Intervention: Milk intake at breakfast
Number of subjects: 22315

Group type: COMPARATOR
Intervention: No milk intake at breakfast
Number of subjects: 22315
Study: 28264794

Group type: EXPERIMENTAL
Intervention: Professional video consent
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Staff video consent
Number of subjects: 665

Group type: COMPARATOR
Intervention: Standard consent
Number of subjects: 665

Group type: COMPARATOR
Intervention: FAQ consent
Number of subjects: 665
Study: 25720929

Group type: EXPERIMENTAL
Intervention: FUSION BIOLINE heparin-coated vascular graft
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard expanded polytetrafluoroethylene (ePTFE) graft
Number of subjects: 209
Study: 24261913

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 140
Study: 21826017

Group type: EXPERIMENTAL
Intervention: Self-reported Chronic Heart Questionnaire (CHQ-SR)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Exercise rehabilitation
Number of subjects: 54
Study: 18853147

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 50
Study: 17304149

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 6 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15085466

Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 anti‐Xa U/kg subcutaneously for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 anti‐Xa U/kg subcutaneously for 90 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous intravenous unfractionated heparin (UFH) for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin for 3 months
Number of subjects: 0
Study: 11499187

Group type: EXPERIMENTAL
Intervention: Oral feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any feedback (oral or written)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written feedback with awards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0
Study: 9773835

Group type: EXPERIMENTAL
Intervention: Food allergy diagnosis based on clinical response to double-blind placebo-controlled food challenge.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Duodenal IgE-positive cells measurement.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Total serum IgE levels measurement.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation of total serum IgE levels with IgE-positive cells.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Delayed reactions to food.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Systemic reactions to foods.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Predictive value of IgE-positive cells in allergy diagnosis.
Number of subjects: 31
Study: 7840913

Group type: EXPERIMENTAL
Intervention: Saquinavir 600 mg in combination with zidovudine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Saquinavir 200 mg in combination with zidovudine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Saquinavir 600 mg alone
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Saquinavir (various doses: 25, 75, 200, 600 mg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 202
Study: 2150891

Group type: EXPERIMENTAL
Intervention: Fenoterol-ipratropium nebulization
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 120
Study: 177866

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside
Number of subjects: 2
Study: 31505120

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 43

Group type: COMPARATOR
Intervention: MICT
Number of subjects: 43
Study: 30846659

Group type: EXPERIMENTAL
Intervention: ChromaGen blue filter lens
Number of subjects: 40

Group type: COMPARATOR
Intervention: No ChromaGen blue filter lens
Number of subjects: 40
Study: 29465203

Group type: EXPERIMENTAL
Intervention: Protective lung ventilation (PLV)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional lung ventilation (CLV)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Preventive bronchoscopy (PB)
Number of subjects: 66
Study: 25922420

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg oral MDMA
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 23724547

Group type: EXPERIMENTAL
Intervention: Filtek Silorane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ceram.X Duo
Number of subjects: 50
Study: 22813412

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 72
Study: 19335074

Group type: EXPERIMENTAL
Intervention: 0.3 mg/ml rhPDGF‐BB + beta‐TCP + bioabsorbable collagen wound‐healing dressing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG) + coronally advanced flap (CAF)
Number of subjects: 30
Study: 17578566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ATP (2 g per dosage)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adenosine (1 g per dosage)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control condition (no indomethacin, no ATP/adenosine)
Number of subjects: 33
Study: 14760130

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.3 microg/kg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Palonosetron 1 microg/kg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Palonosetron 3 microg/kg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Palonosetron 10 microg/kg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Palonosetron 30 microg/kg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Palonosetron 90 microg/kg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Palonosetron (various doses)
Number of subjects: 161
Study: 11123827

Group type: EXPERIMENTAL
Intervention: Weekly doses of 400 mg of ferrous sulphate for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8741946

Group type: EXPERIMENTAL
Intervention: Amphetamine (n = 26)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 37
Study: 1528687

Group type: EXPERIMENTAL
Intervention: High‐High self-efficacy condition
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High‐Low self-efficacy condition
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low‐High self-efficacy condition
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low‐Low self-efficacy condition
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no biofeedback)
Number of subjects: 75
Study: 3881376

Group type: EXPERIMENTAL
Intervention: Various radiation trials
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Adjuvant MOPP chemotherapy
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: New mild adjuvant chemotherapy VBM (vinblastine, bleomycin, and methotrexate) with ABVD in combined modality and alternating regimens
Number of subjects: 800
Study: 29930098

Group type: EXPERIMENTAL
Intervention: 16 Gy SRT
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: 24 Gy SRT
Number of subjects: 230

Group type: COMPARATOR
Intervention: Sham SRT
Number of subjects: 230
Study: 30070576

Group type: EXPERIMENTAL
Intervention: Tactile experience of warmth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control temperatures
Number of subjects: 0
Study: 27381935

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison condition (control)
Number of subjects: 0
Study: 24202298

Group type: EXPERIMENTAL
Intervention: Suicidal geriatric inpatients (intervention group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonsuicidal patients (control group)
Number of subjects: 40
Study: 22126423

Group type: EXPERIMENTAL
Intervention: Alfacalcidol (0.03 µg/kg/day) - Monotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Alfacalcidol and Risedronate (0.05 mg/kg/day) - Polytherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (discontinued medications)
Number of subjects: 30
Study: 19825193

Group type: EXPERIMENTAL
Intervention: Intervention group receiving anticipatory guidance via two modules of six fortnightly parent education and peer support group sessions, followed by six months of regular maintenance contact.
Number of subjects: 820

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 820
Study: 18004908

Group type: EXPERIMENTAL
Intervention: Ortho‐Strips
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: O‐Drive D30
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: New Metal Strips
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Air Rotor
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Profin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Profin and Ortho‐Strips (with polishing)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All groups (with polishing)
Number of subjects: 55
Study: 15109355

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 11913800

Group type: EXPERIMENTAL
Intervention: E 047/1 (1 mg kg(‐1) in pilot study, 2 mg kg(‐1) or 3 mg kg(‐1) bolus in randomized trial)
Number of subjects: 35

Group type: COMPARATOR
Intervention: E 047/1 (2 mg kg(‐1) or 3 mg kg(‐1) bolus)
Number of subjects: 35
Study: 9653596

Group type: EXPERIMENTAL
Intervention: Sex hormone replacement with 17 beta‐estradiol and norethisterone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (normal women, n = 24)
Number of subjects: 26
Study: 8595637

Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine 400 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 2475016

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg twice daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 824047

Group type: EXPERIMENTAL
Intervention: Elective pulmonary irradiation of 1500 rads administered to both lung fields
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no elective pulmonary irradiation)
Number of subjects: 53
Study: 30247715

Group type: EXPERIMENTAL
Intervention: Wii Fit U exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 60
Study: 27538247

Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment
Number of subjects: 0
Study: 26239241

Group type: EXPERIMENTAL
Intervention: Self-administered Internet-based intervention protocol (SII)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical usual care (MUC)
Number of subjects: 100
Study: 23894900

Group type: EXPERIMENTAL
Intervention: Aloe Vera gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine cream
Number of subjects: 50
Study: 21900631

Group type: EXPERIMENTAL
Intervention: Hypothesis-driven examinations
Number of subjects: 16

Group type: COMPARATOR
Intervention: Screening examinations
Number of subjects: 16
Study: 19947796

Group type: EXPERIMENTAL
Intervention: Trauma-specific group (n = 218)
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Trauma-general group (n = 234)
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Non-trauma-exposed group (n = 464)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Non-trauma-exposed participants
Number of subjects: 916
Study: 18042331

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 63

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 63
Study: 14747670

Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake and reduced fat intake
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 393
Study: 10943268

Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 0
Study: 9377833

Group type: EXPERIMENTAL
Intervention: Sulfureous sulfate calcic water of the 'Pergoli' spring-Tabiano (Parma, Italy) (Group II: N. 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (aqua fontis) (Group I: N. 10)
Number of subjects: 20
Study: 8381780

Group type: EXPERIMENTAL
Intervention: Unilateral prefrontal lesion patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study: 3770273

Group type: EXPERIMENTAL
Intervention: Intravenous calcium infusion (calcium gluconate 36.3 mEq/5 h)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 35
Study: 29080520

Group type: EXPERIMENTAL
Intervention: Chamomile therapy
Number of subjects: 45
Study: 27172423

Group type: EXPERIMENTAL
Intervention: One‐day distributed bronchoscopy simulation practice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Weekly distributed bronchoscopy simulation practice
Number of subjects: 20
Study: 25551337

Group type: EXPERIMENTAL
Intervention: 30 motivational interviewing- and social network counseling-based personalized messages
Number of subjects: 72

Group type: COMPARATOR
Intervention: Attention control condition (general health habits texting program)
Number of subjects: 72
Study: 23902614

Group type: EXPERIMENTAL
Intervention: Renal artery sympathetic denervation (RSD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 31
Study: 21650059

Group type: EXPERIMENTAL
Intervention: H‐UPPP
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Plasma-assisted H‐UPPP
Number of subjects: 64
Study: 18342318

Group type: EXPERIMENTAL
Intervention: Broad-range PCR analysis of bacterial DNA signatures from aortic samples
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methodological controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subtraction analysis of bacterial sequences
Number of subjects: 20
Study: 16554683

Group type: EXPERIMENTAL
Intervention: Level 1 treatment studies in spinal cord injury (5 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level 1 treatment studies in traumatic brain injury (15 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level 1 treatment studies in burn rehabilitation (12 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level 2 treatment studies in spinal cord injury (26 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level 2 treatment studies in traumatic brain injury (4 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level 2 treatment studies in burn rehabilitation (2 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-level diagnostic and prognostic studies in spinal cord injury (34 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-level diagnostic and prognostic studies in traumatic brain injury (11 studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-level diagnostic and prognostic studies in burn rehabilitation (5 studies)
Number of subjects: 0
Study: 14627846

Group type: EXPERIMENTAL
Intervention: 11C‐raclopride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Haloperidol (subchronic low dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Haloperidol (higher dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Noise simulations
Number of subjects: 10
Study: 10442670

Group type: EXPERIMENTAL
Intervention: Antiadhesion therapy directed towards phagocyte and endothelial adhesion molecules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of phagocyte activation
Number of subjects: 0
Study: 8541425

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg
Number of subjects: 381

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 381

Group type: COMPARATOR
Intervention: Dextran 70 (historical controls)
Number of subjects: 381
Study: 1835824

Group type: COMPARATOR
Intervention: Sufentanil 3 micrograms.kg‐1 with all pancuronium 1 min after sufentanil (control group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sufentanil 3 micrograms.kg‐1 with 1 mg pancuronium 1 min before sufentanil and the balance of pancuronium 1 min after sufentanil (pretreated group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sufentanil 3 micrograms.kg‐1 with all pancuronium mixed with sufentanil (mixed group)
Number of subjects: 57
Study: 7282603

Group type: EXPERIMENTAL
Intervention: 1.4 g omega 3 fatty acids
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2.3 g omega 3 fatty acids
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 4.1 g omega 3 fatty acids
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 8.2 g omega 3 fatty acids
Number of subjects: 52
Study: 29368994

Group type: EXPERIMENTAL
Intervention: Message to avoid antipsychotic medications
Number of subjects: 158

Group type: COMPARATOR
Intervention: Managerial oversight
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Actual facility antipsychotic prevalence
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Avoid antipsychotics message
Number of subjects: 158
Study: 28526947

Group type: EXPERIMENTAL
Intervention: UC patients with TCN2 (rs1801198) genotypes
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: UC patients
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: HHcy and folate deficiency
Number of subjects: 527
Study: 26224752

Group type: EXPERIMENTAL
Intervention: Short retention interval (RI)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Long retention interval (RI)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Forward prompts
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Meal-name prompts
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Open prompts
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Reverse prompts
Number of subjects: 480
Study: 24122767

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab with 2 mg/kg conatumumab
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab with 10 mg/kg conatumumab
Number of subjects: 202

Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab with placebo
Number of subjects: 202
Study: 20049495

Group type: EXPERIMENTAL
Intervention: Metallic matrix and wooden wedge
Number of subjects: 23

Group type: COMPARATOR
Intervention: Polyester matrix and reflective wedge
Number of subjects: 23
Study: 18758971

Group type: COMPARATOR
Intervention: Smoking cessation pharmacotherapy
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Confidence to quit smoking
Number of subjects: 263
Study: 16862288

Group type: EXPERIMENTAL
Intervention: Oral T3, 25 microg three times/day, initiated 24 h before surgery and maintained for 48 h
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (NT group)
Number of subjects: 18
Study: 15561516

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine treatment for 4 weeks
Number of subjects: 91

Group type: COMPARATOR
Intervention: Waiting list control group (continued previous headache treatment)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 91
Study: 12555604

Group type: EXPERIMENTAL
Intervention: Reading on paper in their mother tongue
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading on screen in their mother tongue
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading on paper in English
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading on screen in English
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading in their mother tongue (combined)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Reading in English (combined)
Number of subjects: 114
Study: 11995034

Group type: EXPERIMENTAL
Intervention: NLA general anaesthesia
Number of subjects: 45

Group type: COMPARATOR
Intervention: Spinal analgesia
Number of subjects: 45
Study: 9050617

Group type: EXPERIMENTAL
Intervention: Laparoscopy for chronic pelvic pain
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopy for tubal sterilization (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Right-sided paracolic adhesions
Number of subjects: 80
Study: 2202093

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid plus dipyridamole
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 2500
Study: 318894

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg oral dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6753769

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 32

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 32
Study: 30461557

Group type: COMPARATOR
Intervention: diet + exercise
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: diet
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: weight loss maintenance
Number of subjects: 439
Study: 29515001

Group type: EXPERIMENTAL
Intervention: Smartphone-based blood pressure monitoring device
Number of subjects: 62

Group type: COMPARATOR
Intervention: Finger cuff device (control)
Number of subjects: 62
Study: 26720622

Group type: EXPERIMENTAL
Intervention: Intervention arm with flexibility in duty hour policies (ACGME waiver allowing deviation from current standards)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care arm adhering to current ACGME resident duty hour standards
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intervention arm with flexibility in duty hour policies
Number of subjects: 118
Study: 25291116

Group type: COMPARATOR
Intervention: Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01 delivered via slow-release vaginal tablets (400 million live cells per dose) for 7 consecutive nights followed by 1 tablet every 3 nights for 3 weeks and then 1 tablet per week for long-term maintenance.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo group (no significant differences recorded at any time).
Number of subjects: 34